On December 15, 2022, the Center for Translational Research held the 2022 Year-end Summary Meeting. Nearly 50 people, including leaders of the Center, leaders of each team and some representatives of scientific researchers, attended the meeting which was presided over by Dr. Shen Weijun, Director of the Center for Translational Research. In the meeting, each research team reported the academic progress and introduced the work plan of the next year.
Dr. Shen Weijun, Director of the Center, expressed his welcome to all the participants and made a concise summary of the Center’s work in 2022. He said, since its establishment, the Center has developed rapidly, and has made good achievements in the establishment of software and hardware platform for new drug development, the building of core talent team, the promotion of new drug R&D pipeline and foreign cooperation, which owed to the joint efforts of all colleagues. He hoped that this meeting would facilitate the research teams to actively carry out academic exchanges and collaborate in new drug development to jointly promote the Center for Translational Research to be an international first-class one.
The meeting was divided into morning and afternoon sessions. In the morning, more than 10 team leaders of the Center reported this year’s work respectively.
In the afternoon (closed meeting of the Center), the Director of the Center and the project leaders had in-depth discussions on the highlights and the improvement to be made of the Center’s work in 2022, and made the research and development goals for 2023.
This meeting reviewed the scientific research progress made by the Center for Translational Research in 2022, provided an opportunity for the research teams to communicate together and share new ideas and new strategies for new drug research and development, so as to jointly promote the Center into a new stage of rapid development.
